Literature DB >> 25247851

Rapid in vivo detection of isoniazid-sensitive Mycobacterium tuberculosis by breath test.

Seong Won Choi1, Mamoudou Maiga2, Mariama C Maiga2, Viorel Atudorei3, Zachary D Sharp3, William R Bishai2, Graham S Timmins1.   

Abstract

There is urgent need for rapid, point-of-care diagnostic tools for tuberculosis (TB) and drug sensitivity. Current methods based on in vitro growth take weeks, while DNA amplification can neither differentiate live from dead organisms nor determine phenotypic drug resistance. Here we show the development and evaluation of a rapid breath test for isoniazid (INH)-sensitive TB based on detection of labelled N2 gas formed specifically from labelled INH by mycobacterial KatG enzyme. In vitro data show that the assay is specific, dependent on mycobacterial abundance and discriminates between INH-sensitive and INH-resistant (S315T mutant KatG) TB. In vivo, the assay is rapid with maximal detection of (15)N2 in exhaled breath of infected rabbits within 5-10 min. No increase in (15)N2 is detected in uninfected animals, and the increases in (15)N2 are dependent on infection dose. This test may allow rapid detection of INH-sensitive TB.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25247851      PMCID: PMC4182730          DOI: 10.1038/ncomms5989

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


Introduction

Bacterially-activated prodrugs are unusually well-represented among the first- and second-line TB drugs. These include not only established drugs such as isoniazid [1], ethionamide [2] or pyrazinamide [3], but also newly approved and developing agents such as the nitroimidazoles delamanid [4] and PA-824 [5]. The selectivity of these agents arises from their specific activation by mycobacterial enzymes, usually to reactive intermediates, and is underlined by the major mode of resistance to these agents being mutations in genes of their activating enzymes such as katG for INH [6], ethA for ethionamide [7], pncA for pyrazinamide [8] and ddn for nitroimidazoles [9]. Since gene inactivation may occur through a multiplicity of single nucleotide polymorphisms (SNPs) or insertion/deletion (indel) events, nucleic acid amplification and SNP-indel detection approaches provide only partially predictive drug susceptibility data. Beyond single gene mutational resistance, multiple other alleles [10-14] and other drugs [15,16] may influence enzymatic activity of prodrug conversion, factors that may also limit nucleic acid based techniques for drug susceptibility testing. Despite the importance of prodrug activation, studies have been limited to in vitro samples or bacterial culture, and at present there are no POC techniques to directly measure prodrug conversion and enzymatic activity. The mycobacterial enzyme KatG, which is responsible for INH activation, produces a range of INH-derived radicals that react with cellular components, especially the isonicotinoyl acyl radical (INAcyl) that adds covalently to NAD+ and NADP+. The adducts formed by these radicals are potent inhibitors of key mycobacterial targets. The first target of such inhibition to be elucidated was 2-trans-enoyl-acyl carrier protein reductase (InhA) which binds INacyl-NAD+ adducts tightly inhibiting mycolic acid synthesis [17]. Although other targets or reactive species may play roles, the importance of these alternative mechanisms compared to the widely accepted inhibition of InhA remains unclear [18]. The detection of degradation products of the INacyl-NAD+ adduct, such as 4-isonicotinoylnicotinamide (4-INN) in urine or other fluids held great promise as a measure of INH prodrug conversion in TB, and so determining KatG activity [19]. However, this appears to lack specificity for M. tuberculosis as 4-INN was found in urine of uninfected mice treated with INH, and in urine of TB patients even when they were culture-negative after treatment [19]. Mycobacterial KatG activates INH by oxidation to a hydrazyl radical that undergoes beta scission to form INAcyl radical. The other product of this beta-scission reaction, diazene, has received little to no attention in the literature. To study diazene production in KatG expressing mycobacteria, we used doubly 15N2-hydrazyl labeled INH (1) to produce doubly labeled diazene (Fig. 1A). Under physiologic conditions this diazene rapidly undergoes either oxidation by unsaturated bonds (Figure 1b) [20] or bimolecular disproportionation (Figure 1c) to produce 15N2 [21]. Diazene is widely used synthetically in the stereospecific reduction of a wide range of carbon-carbon double bonds [22].
Fig. 1

Production of N2 from KatG ctivation of Isoniazid

(A) Production of labeled diazene from 15N2-hydrazyl- INH; (B) oxidation of diazene to N2 by reaction with unsaturated carbon bonds such as fumarate shown, rate constant 8 × 102 M−1 s−1 20; (C) disproportionation of diazene to N2 and hydrazine rate constant 2.2 × 104 M−1 s−1 21.

This 15N2 produced from INH-derived diazene may be readily detected by isotope ratio mass spectrometry (IRMS), and its abundance is reported as δ15N2 where δ15N2 = 1000 x [(15N15N /14N14N)Sample- (15N15N/14N14N)Standard](15N15N/14N14N)Standard Atmospheric 15N is much lower in abundance than 14N (~ 0.36%), hence 15N2 is very low in abundance (~ 13 ppm) so even small amounts of 15N2 generation may be detected through changes in δ15N2. For example, an increase in the value of δ15N2 of 250 would indicate a 25% increase in the absolute amount of 15N2 in a sample. This same principle is exploited by other isotope ratio breath diagnostics including the urease breath test for of Helicobacter pylori infection. In this report, we describe the detection of 15N2 products of INH activation that are specific for mycobacterial KatG, and test their specificity against other important lung bacterial pathogens that possess related peroxidase enzymes. By measuring the increase over baseline δ15N2 upon addition of the 15N2-hydrazyl INH (a method termed INH→N here) , we hypothesized that IRMS detection of this 15N2 may allow sensitive measurement of INH activation by KatG.

Results

In vitro cultures of Mycobacterium tuberculosis H37Rv or Mycobacterium bovis BCG were treated with 15N2-hydrazyl INH in sealed tubes and portions of headspace gas collected, filtered and analyzed. Treatment with 1 mg/ml 15N2-hydrazyl INH resulted in marked increases in δ 15N2 which were dependent upon bacterial density (CFU/ml) (Fig. 2A). Next we determined the correlation between the accumulated δ15N2 and the dose of 15N2-hydrazyl INH administered (Fig. 2B), and these experiments showed sensitive IRMS detection of headspace δ15N2 following 15N2-hydrazyl INH doses of 0.1 mg/ml, a concentration we subsequently used throughout. The generation of headspace δ15N2 occurred rapidly (Fig. 2C), and plateau levels were reached in approximately one hour. Similar data were also observed with M. bovis BCG (Fig. 3) another KatG-expressing mycobacterial species, although generally lower levels of 15N2 production were observed compared to M. tuberculosis H37Rv. These data confirmed our ability to measure of mycobacterial KatG activity quantitatively by IRMS monitoring of conversion of 15N2-hydrazyl INH to 15N2 using in vitro cultures of mycobacteria.
Fig. 2

CFU, Dose and Time Dependence of 15N2 Production by M. tuberculosis H37Rv

Increased headspace δ15N2 (mass 30) in 15N2-hydrazyl INH–treated cultures. 15N2 production was dependent upon: (A) bacterial density of M. tuberculosis H37Rv (3 ml) incubated with 15N2-hydrazyl-INH (1 mg/ml) for 1 hour, *p<0.001; (B) concentration of 15N2-hydrazyl INH (H37Rv (108 CFU/ml, 3 ml) was incubated with 15N2-hydrazyl-INH at the indicated dose for 1 hour, *p<0.001); (C) incubation time (H37Rv (108 CFU/ml, 3 ml) was incubated with 15N2-hydrazyl-INH (0.1 mg/ml) for the indicated time, *p<0.001). Data represent mean ± STD of 4 separate biological replicates. One-way ANOVA with Tukey post hoc test.

Fig. 3

CFU, Dose and Time Dependence of 15N2 Production by M. bovis BCG

Increased headspace δ5N2 (mass 30) in 15N2-hydrazyl INH–treated cultures was dependent upon: (A) bacterial density of M. bovis BCG (3 ml) incubated with 1 mg/ml of 15N2-hydrazyl-INH for 1 hour, *p<0.001; (B) concentration of 15N2-hydrazyl INH (M. bovis BCG (108 CFU/ml, 3 ml) was incubated with 15N2-hydrazyl-INH at the indicated dose for 1 hour, *p<0.001); (C) incubation time (M. bovis BCG (108 CFU/ml, 3 ml) was incubated with 15N2-hydrazyl-INH (1 mg/ml) for the indicated time, *p<0.001). Data represent mean ± STD of 3 separate biological replicates. One-way ANOVA with Tukey post hoc test.

We then evaluated the specificity of our 15N2-hydrazyl INH to 15N2 detection method for mycobacterial KatG activity. As may be seen in Fig. 4A the common respiratory pathogens S. aureus, P. aeruginosa and E. coli did not produce 15N2 when treated with 15N2-hydrazyl INH. To determine whether our 15N2-hydrazyl INH to 15N2 detection method for INH prodrug conversion was specific for the mycobacterial KatG, we tested the production of 15N2 using an M. tuberculosis strain harboring a mutated KatG. This strain possessed the M. tuberculosis katG-S315T mutation that is known to profoundly decrease INH activation and result in drug resistance.[6] When compared to M. tuberculosis H37Rv, we found the katG-S315T mutant did not produce any measurable 15N2 (Fig. 4B).
Fig. 4

Specificity of 15N2 production

(A) Increased headspace δ 15N2 in 15N2-hydrazyl INH treated overnight cultures of S. aureus, P. aeruginosa and E. coli compared to M. tuberculosis H37Rv. Bacterial culture (108 CFU/ml, 3 ml) was incubated with 15N-INH (0.1 mg/ml) for 1 hour. Data represent mean ± STD (n=3 biological replicates). Students’ t-test, *p<0.001. (B) Comparison in headspace δ15N2 in 15N2-hydrazyl INH-treated drug-sensitive M. tuberculosis H37Rv, and an INH-resistant KatG mutant strain (katGS315T). H37Rv or katG-S315T strains (108 CFU/ml, 3 ml) were incubated with 15N2-hydrazyl INH (0.1 mg/ml) for 1 hour. Data represent mean ± STD (n=4 biological replicates). Students’ t-test, *p<0.005.

These in vitro characteristics supported our hypothesis that the 15N2-hydrazyl INH to 15N2, INH→N detection method might be used to detect KatG activation of INH in vivo, using a breath test approach [23,24]. Rabbits were infected with high dose (104 CFU) or low dose (103 CFU) M. tuberculosis H37Rv using an inhalation exposure system (Glas-col) as previously described[25]. After a six week incubation period, rabbits were treated with 10 mg of 15N2-hydrazyl INH instilled bronchoscopically. Direct delivery to the lung was chosen to rapidly expose lung bacteria to 15N2-hydrazyl INH in order to allow rapid assay, as opposed to an oral dosage form which would require absorption and redistribution. Inhaled INH has been used clinically in humans.[26] Breath samples were collected prior to dosing, and then at 5, 10 and 20 minutes post-dose. Four non-infected rabbits were used as control group. It was seen that δ15N2 increased rapidly in breath of all infected animals, with no observed increase in breath δ15N2 of the four uninfected controls (Fig. 5A, 5B). The lack of signal in uninfected animals, together with significant signals in all infected animals, suggests that a high degree of sensitivity and specificity is inherent in this assay. Breath δ15N2 reached a maximum after 5 to 10 minutes, and then variably decreased, likely due to differential distribution and absorption of 15N2-hydrazyl INH from the lung into systemic circulation from the more focal pattern of delivery arising from instillation. A relationship between peak levels of δ15N2 and lung CFU was observed (Fig. 6A and 6B reflecting δ15N2 as a function of lung CFU at sacrifice and initial infective CFU respectively). This suggests the approach might be sensitive to the amount of lung mycobacteria present, although significant further work is needed to delineate this relationship. Repetitive use of the technique is also likely to be complicated by the highly bactericidal nature of inhaled INH, and for monitoring of bacterial load other techniques such as urease breath tests [23] or sputum CFU may be more useful.
Fig. 5

In vivo 15N2 Production in TB-Infected and Control rabbits

Increased breath in (A) high dose, and (B) low dose TB infected rabbits. Rabbits were infected with high or low doses of M. tuberculosis H37Rv, instilled with 10 mg 15N2-hydrazyl INH and breath collected. Rabbits (pathogen-free outbred New Zealand White) were infected with the indicated CFU by aerosol. At week 6, rabbits were anesthetized with ketamine (15-25 mg/kg) and xylazine (5-10 mg/kg), and treated with 15N2-hydrazyl-INH (10 mg/ in 0.4 ml phosphate buffered saline) by intratracheal intubation. Exhaled breath gas (12 ml) was collected into Helium gas–flushed tubes at 0, 5, 10, and 20 min post 15N2-hydrazyl INH administration. Data represent mean ± STD (n=3 repeats for each rabbit N3 through N6, n=12 for four uninfected control rabbits with 3 repeats for each). Two-way mixed ANOVA with Bonferroni post hoc test. *p<0.001. See detailed rabbit data in Table 1.

Fig. 6

Dependence of peak increase in breath δ15N2 upon infection level

The maximal increase in breath δ 15N2 after 15N2-hydrazyl INH delivery in Fig.5 is plotted here as a function of (A) lung CFU determined at sacrifice, and (B) initial infective dose delivered. Rabbit identity numbers are shown, and 95% confidence limits presented as dashed lines.

Discussion

The INH→N detection method for mycobacterial KatG activity described here is capable of discriminating between INH susceptible and resistant M. tuberculosis and between KatG-expressing mycobacteria and other common lung pathogens in vitro. It is also capable of rapidly discriminating between controls and animals infected with INH-susceptible TB. Potential advantages of the INH→N test are the rapid non-radioactive breath test approach, based upon detecting prodrug activation, and that samples the entire lung. The readout of this test, 15N2, is detected using IRMS, and portable MS detection devices are available and under development [29] supporting eventual development into a POC technology. Residual gas analyzer MS, a technique with great potential for portability, has recently been shown effective in clinical IRMS[30], and represents one avenue forwards. As with any new potential diagnostic approach, ultimate clinical usage and utility must be determined in trials. Clinically, high-level INH resistance is strongly correlated to katG-S315T mutations with greatly lowered INH activating (and INH→N) activity, whereas lower level resistance is associated with inhA promoter mutations that will likely not be differentiated from INH sensitive strains by the INH→N test [31]. However, INH→N assay would allow rapid point of care detection of katG-S315T and other katG mutations as part of a diagnostic approach, to enable rapid and optimal therapy. The potential for the INH→N method to report as a rapid and specific biomarker of mycobacterial load may provide useful tool for monitoring clinical trials and therapeutic efficacy. INH→N may also prove useful in diagnosis of some non-tuberculous mycobacteria, such as INH-sensitive M. kansasii, [32] that can otherwise be challenging. However, since some peroxidases other than mycobacterial KatG enzymes bind INH (such as lactoperoxidase [33]) further studies of specificity are planned. Similar approaches may also be extended to other TB prodrug classes so that effective and rapid detection of drug sensitivity/resistance through prodrug conversion can guide therapy. One example would be Delamanid and PA824 that are activated to bactericidal NO· by mycobacterial Ddn[5] : using 15N-nitro-PA824 would result in 15NO· that could be directly detected in breath, or as 15N-nitrate/nitrite in other samples such as blood or urine. This could provide rapid detection of drug activation (and hence sensitivity) in patients when conventional techniques such as MS detection of des-nitro-PA824 are difficult (Clif Barry, personal communication). This would allow optimal use of these drugs in therapy of multi-drug resistant (MDR) and extensively-drug resistant (XDR) disease. More generally, while pathogen genotypes are rapidly determined without culture, the study of bacterial phenotypes in the host (as opposed to culture in which it can greatly change) is extremely challenging. However, the broad importance of phenotype and phenotype variance in pathogenesis is becoming increasingly appreciated, with specific examples of both growth phase-dependent [34] and stochastic [35] isoniazid resistant phenotypes being recently elucidated. The ability to determine bacterial phenotypes through stable isotope detection of specific bacterial metabolic pathways without requiring culture could prove broadly valuable in complementing genomic approaches in studying microbiomes. Finally, it is worth noting that yet another reactive species from mycobacterial KatG activation of INH, in this case diazene, could play a role in INH action through reducing key unsaturated mycobacterial molecules.

Methods

Bacterial cultures

Mycobacterium tuberculosis

H37Rv (H37Rv), M. bovis BCG, E.coli DH5α and P. aeruginosa PAO1 were gifts from Professor Vojo Deretic,[37,38] M. tuberculosis katGS315T (katG-S315T) was a gift from Professor Alex Pym [36]. S. aureus USA300 LAC was a gift from Professor Pamela Hall [39]. All bacterial cultures were grown at 37°C with shaking. Mycobacterium cultures were prepared by thawing frozen stock aliquots: H37Rv and katG-S315T were grown in 7H9 Middlebrook liquid medium supplemented with oleic acid, albumin, dextrose and catalase (Becton Dickinson, Inc., Sparks, MD), 0.5% glycerol and 0.05% Tween 80. BCG was grown in the same culture medium omitting oleic acid. Escherichia coli DH5α was grown overnight in LB broth (Becton Dickinson), Pseudomonas aeruginosa strain PAO1 was grown overnight in LB broth supplemented with 1.76% NaCl and 1% glycerol, and Staphylococcus aureus USA300 LAC was grown overnight in BBL Trypticase soybroth (Becton Dickinson).

In vitro KatG assay

3 ml of mycobacterial cultures (BCG, H37Rv or katG-S315T) were diluted as appropriate from week-old cultures, while other bacterial cultures (P. aeruginosa, E. coli or S. aureus) were diluted from overnight cultures. The 3 ml cultures were shaken aerobically and then were incubated with 15N2-hydrazyl INH (at 0.1 mg/ml unless noted) in 12 ml Exetainer vials (Labco Ltd., Ceredigion, UK) for 1 hour at 37 with shaking at 250 rpm unless otherwise indicated. Collected headspace gas (1 ml) was filtered through 0.25 micron syringe filters and transferred into Helium-flushed Exetainers.

Measurement of 15N2 conversion

Sampled gas was analyzed for 15N enrichment in headspace N2 by gas isotope ratio mass spectrometry (DeltaplusXL, Thermo Scientific Inc. Waltham, MA). Samples were separated by GC immediately upstream of their inlet into the IRMS using a 30 m column packed with 5 Å molecular sieves operating at 60°C and using ultra high purity helium as carrier gas. IRMS of the N2 peak measured relative ratio of mass 30 15N2 vs. mass 28 14N2. Nitrogen gas of purity >99.99% (Matheson Tri-Gas, Albuquerque, NM) was used as reference gas.

Animal experiments

These consisted of four uninfected control rabbits, two rabbits infected at high dose (N3 and N4) and two rabbits infected at low dose (N5 and N6). Rabbits (females, 16-20 weeks old, 3.5 - 4 Kg pathogen-free outbred New Zealand White, Robinson Services, Inc., Mocksville, NC) were aerosol infected with M. tuberculosis H37Rv at either 103 or 104 CFUs using an inhalation exposure system as previously described[40] (Glas-col, Terre Haut, IN). At week 6, rabbits were anesthetized with ketamine 15-25 mg/kg and xylazine 5-10 mg/kg, and then 10 mg 15N2-hydrazyl-INH in 0.4 ml saline was instilled using intra-tracheal insertion through an endotracheal tube. To collect breath gas, a 14-French feeding tube connected to a 30 ml syringe was introduced through the endotracheal tube into the level of the carina to aspirate the exhaled air when rabbit is breathing out. Breath gas (12 ml) was filtered with a 0.35-micron filter into Helium-flushed tubes before and after 15N2-hydrazyl-INH treatment at 0, 5, 10, and 20 min. 15N2 enrichment in breath gas was measured by IRMS. Immediately after breath testing, the animals were euthanized, and lung weight and CFU measured (Table 1. Rabbits were euthanized with intravenous euthasol (Virbac Corporation, Fort Worth, TX). The rabbit model was chosen as it is the smallest model that enables ready endoscopic infection, instillation of INH, and collection of breath.
Table 1

Details of TB-infected rabbits.

Rabbit ID#N3N4N5N6
Inoculum size 104 CFU104 CFU103 CFU103 CFU
CFU / g lung at sacrifice 1.8 × 105ND7.6 × 1047.4 × 104
Lung weight (g) 58ND12.514.1
Total lung CFU 1 × 107ND9.4 × 1051 × 106

ND, not performed.

Ethics statement

Animal work in this study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, the Animal Welfare Act and US federal law. The protocol was approved by the Institutional Animal Care and Use Committees at Johns Hopkins University (RB11M466).

Statistical analysis

All statistical analyses were performed using SPSS version 19 (SPSS Inc., Chicago, IL). P values were determined using ANOVA and Students’ t-test, and values <0.05 considered statistically significant.
  38 in total

1.  Strain-dependent CNS dissemination in guinea pigs after Mycobacterium tuberculosis aerosol challenge.

Authors:  Nicholas A Be; Lee G Klinkenberg; William R Bishai; Petros C Karakousis; Sanjay K Jain
Journal:  Tuberculosis (Edinb)       Date:  2011-08-09       Impact factor: 3.131

2.  Handheld miniature ion trap mass spectrometers.

Authors:  Zheng Ouyang; Robert J Noll; R Graham Cooks
Journal:  Anal Chem       Date:  2009-04-01       Impact factor: 6.986

3.  Mapping of Mycobacterium tuberculosis katG promoters and their differential expression in infected macrophages.

Authors:  S Master; T C Zahrt; J Song; V Deretic
Journal:  J Bacteriol       Date:  2001-07       Impact factor: 3.490

4.  Activation of the pro-drug ethionamide is regulated in mycobacteria.

Authors:  A R Baulard; J C Betts; J Engohang-Ndong; S Quan; R A McAdam; P J Brennan; C Locht; G S Besra
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

5.  ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates.

Authors:  Glenn P Morlock; Beverly Metchock; David Sikes; Jack T Crawford; Robert C Cooksey
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

6.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

7.  Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis.

Authors:  Raymund Dantes; John Metcalfe; Elizabeth Kim; Midori Kato-Maeda; Philip C Hopewell; Masae Kawamura; Payam Nahid; Adithya Cattamanchi
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

8.  Nox2 modification of LDL is essential for optimal apolipoprotein B-mediated control of agr type III Staphylococcus aureus quorum-sensing.

Authors:  Pamela R Hall; Bradley O Elmore; Cynthia H Spang; Susan M Alexander; Brett C Manifold-Wheeler; Moriah J Castleman; Seth M Daly; M Michal Peterson; Erin K Sully; Jon K Femling; Michael Otto; Alexander R Horswill; Graham S Timmins; Hattie D Gresham
Journal:  PLoS Pathog       Date:  2013-02-14       Impact factor: 6.823

9.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714

10.  In vitro and in vivo studies of a rapid and selective breath test for tuberculosis based upon mycobacterial CO dehydrogenase.

Authors:  Mamoudou Maiga; Seong Won Choi; Viorel Atudorei; Mariama C Maiga; Zachary D Sharp; William R Bishai; Graham S Timmins
Journal:  mBio       Date:  2014-04-15       Impact factor: 7.867

View more
  3 in total

1.  Detecting virulence and drug-resistance mycobacterial phenotypes in vivo.

Authors:  Graham S Timmins
Journal:  Trends Microbiol       Date:  2015-03-21       Impact factor: 17.079

Review 2.  Stable isotope biomarker breath tests for human metabolic and infectious diseases: a review of recent patent literature.

Authors:  Graham S Timmins
Journal:  Expert Opin Ther Pat       Date:  2016-08-10       Impact factor: 6.674

3.  Ultrasensitive multiplex optical quantification of bacteria in large samples of biofluids.

Authors:  Nicolas Pazos-Perez; Elena Pazos; Carme Catala; Bernat Mir-Simon; Sara Gómez-de Pedro; Juan Sagales; Carlos Villanueva; Jordi Vila; Alex Soriano; F Javier García de Abajo; Ramon A Alvarez-Puebla
Journal:  Sci Rep       Date:  2016-07-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.